New dual-action insulin to help people who can't feel low blood sugar
Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)
Testing a dual-action insulin designed to prevent dangerous low blood sugars in adults with diabetes who have impaired awareness of hypoglycemia.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Amidebio, LLC NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11176960 on NIH RePORTER |
What this research studies
You would be hearing about a new drug called a molecular artificial pancreas, a dual-acting insulin designed to stop low blood sugar before it becomes dangerous. The company will make and formulate these drug candidates and move directly into Phase II testing to see how they work in people. Early lab and preclinical work showed the approach can prevent hypoglycemia at high doses, and this project aims to test safety and benefit under clinical supervision. Participants would have blood sugar and symptoms closely monitored while receiving the study medication.
Who could benefit from this research
Good fit: Adults (age 21 and older) with diabetes who have impaired awareness of hypoglycemia or frequent insulin-related low blood sugars would be the intended participants.
Not a fit: People who do not have impaired hypoglycemia awareness, those not treated with insulin, pregnant individuals, or people with specific medical exclusions may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this approach could reduce severe low-blood-sugar episodes and lower emergency visits for people with impaired hypoglycemia awareness.
How similar studies have performed: Preclinical and early laboratory studies have shown promising prevention of hypoglycemia, but human effectiveness is still largely unproven and the approach is relatively novel.
Where this research is happening
Louisville, United States
- Amidebio, LLC — Louisville, United States (Active)
Researchers
- Principal investigator: Fludzinski, Pawel — Amidebio, LLC
- Study coordinator: Fludzinski, Pawel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.